AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

New European initiative to accelerate drug discovery for cardiometabolic diseases

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm...

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline.

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies

WATERTOWN, Mass. and CINCINNATI, June 18, 2026 (GLOBE NEWSWIRE) -- Constantiam Biosciences and Cincinnati Children's today announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3).

Diazyme Laboratories, Inc. Announces FDA 510(k) Clearance for Lipoprotein(a) Molarity Assay

Diazyme receives FDA 510(k) clearance for its isoform‑independent Lipoprotein(a) Molarity Assay, improving standardized cardiovascular risk assessment.

Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities

BLUE ASH, Ohio, June 18, 2026 (GLOBE NEWSWIRE) -- Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today announced the relocation of Resilience’s corporate headquarters from San Diego, California to Blue Ash, Ohio, a northern suburb of Cincinnati. Resilience is a leading biomanufacturing contract and development manufacturing organization (CDMO) dedicated to broadening access to complex medicines, with a large drug product manufacturing facility in West Chester, Ohio. This move strengthens the company’s operational footprint in the state, and reinforces Ohio’s position as a growing hub for pharmaceutical and sterile manufacturing innovation.

Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470

Attachment

WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety...

F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in...


MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/SASKATOON, SK, June 17, 2026 /CNW/ - ZYUS Life Sciences Corporation...

MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders

MediPharm Labs announces the results of matters voted on at its annual and special meeting of shareholders held today.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers